Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model

The Journal of International Medical Research
Z HeC Wang

Abstract

In a rat renal allograft model, the long-term effect of conversion from cyclosporin A (CsA) to sirolimus on recipient kidneys and growth factor expression were compared with continuous use or withdrawal of CsA. Kidneys from Fisher 344 rats were orthotopically transplanted into Lewis rats. Four Fisher 344 to Lewis allograft groups were treated post-transplant as follows: (i) CsA (transplant to week 8) then sirolimus (weeks 8 - 24); (ii) CsA (transplant to week 24); (iii) CsA (transplant to week 8) then vehicle (weeks 8 - 24); (iv) control vehicle (transplant to week 24). A fifth group underwent syngeneic isograft (Lewis to Lewis) with no drug treatment. Proteinuria was measured every 4 weeks and grafts harvested at 24 weeks for morphological and immunohistochemical analysis. Conversion from CsA to sirolimus resulted in a significant decrease in proteinuria at 24 weeks, a lower Banff sum score and lower expression of transforming growth factor mRNA compared with continuous use or withdrawal of CsA. In conclusion, conversion from CsA to sirolimus retarded progression of chronic allograft nephropathy in the rat model.

References

Feb 1, 1973·Transplantation·T X O'Connell, J F Mowbray
Oct 27, 1996·Transplantation·J F DiJosephS N Sehgal
May 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·E C Muchaneta-Kubara, A M el Nahas
Jan 16, 1999·Journal of the American Society of Nephrology : JASN·P F HalloranC Barth
Feb 13, 1999·Kidney International·L C RacusenY Yamaguchi
Mar 20, 1999·Transplantation Proceedings·H J SchuurmanC Bruns
May 7, 1999·Kidney International·R B MannonT M Coffman
Mar 4, 2000·The New England Journal of Medicine·S HariharanD Stablein
Mar 9, 2000·Transplantation·O ViklickýU Heemann
Feb 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Bertram L KasiskeArthur J Matas
May 14, 2003·Transplantation Proceedings·M F EgidiA O Gaber
Nov 25, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Fuad S ShihabTakeshi F Andoh
Dec 12, 2003·The New England Journal of Medicine·Brian J NankivellJeremy R Chapman
Mar 17, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Barbara SuwelackHelge Hohage
Jun 30, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Viorica BumbeaLionel Rostaing
Sep 16, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Christopher J E WatsonJ Andrew Bradley
Oct 21, 2005·Journal of the American Society of Nephrology : JASN·Giovanni StalloneGiuseppe Grandaliano
Dec 13, 2005·Kidney International. Supplement·Jeremy R Chapman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.